Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 11
2004 8
2005 7
2006 13
2007 12
2008 11
2009 10
2010 13
2011 16
2012 15
2013 15
2014 24
2015 23
2016 16
2017 16
2018 19
2019 15
2020 25
2021 35
2022 33
2023 24
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

298 results

Results by year

Filters applied: . Clear all
Page 1
Testicular cancer.
Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, Looijenga LHJ. Cheng L, et al. Among authors: albers p. Nat Rev Dis Primers. 2018 Oct 5;4(1):29. doi: 10.1038/s41572-018-0029-0. Nat Rev Dis Primers. 2018. PMID: 30291251 Review.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Among authors: albers p. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
Editorial comment.
Bagrodia A, Albers P. Bagrodia A, et al. Among authors: albers p. Curr Opin Urol. 2018 Sep;28(5):433-434. doi: 10.1097/MOU.0000000000000524. Curr Opin Urol. 2018. PMID: 30044318 No abstract available.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Bellmunt J, et al. Among authors: albers p. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
Reply by Authors.
Nestler T, Paffenholz P, Pfister D, Schoch J, Nini A, Hiester A, Albers P, Heidenreich A. Nestler T, et al. Among authors: albers p. J Urol. 2024 Mar;211(3):435. doi: 10.1097/JU.0000000000003812.02. Epub 2024 Feb 8. J Urol. 2024. PMID: 38329048 No abstract available.
Special Issue on Testis Cancer.
Nettersheim D, Albers P. Nettersheim D, et al. Among authors: albers p. World J Urol. 2022 Feb;40(2):305-306. doi: 10.1007/s00345-022-03957-w. World J Urol. 2022. PMID: 35226139 Free PMC article. No abstract available.
Testicular germ cell tumors.
Albers P. Albers P. Asian J Urol. 2021 Apr;8(2):143. doi: 10.1016/j.ajur.2021.02.002. Epub 2021 Feb 19. Asian J Urol. 2021. PMID: 33996468 Free PMC article. No abstract available.
Reply by Authors.
Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Fossati N, et al. Among authors: albers p. J Urol. 2020 Aug;204(2):302. doi: 10.1097/JU.0000000000000800.03. Epub 2020 May 19. J Urol. 2020. PMID: 32427046 No abstract available.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Sternberg CN, et al. Among authors: albers p. Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25498218 Free article. Clinical Trial.
298 results